Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific Expects Synergy To Dominate Drug-Eluting Stents In US

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific wants to expand the lead against other stents used by interventional cardiologists with the launch of its Synergy drug-eluting stent that they expect will become the workhorse of the industry to handle a broad range of surgeries to treat coronary artery disease. "Our belief is that the target for Synergy is [the] entire market," says Boston Scientific's senior VP and president of its interventional cardiology unit.

Advertisement
Advertisement

Related Content

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT034273

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel